Topical and subconjunctival anti-VEGF agents have been used in a few studies for primary or recurrent ocular surface squamous neoplasia (OSSN) in humans, yielding mostly favorable clinical results without any ocular or systemic side effects [29,30,31,32,33]. This evidence concerns the gene VEGFA and conjunctival squamous cell carcinoma.